Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are interrelated inflammatory conditions, and evidence suggests that infection and vaccination might act as a trigger for these conditions. This descriptive systematic review summarizes the published case reports and case series on new-onset PMR and GCA following COVID-19 vaccination, highlighting their clinical features, diagnostic findings, and treatment outcomes.
Objectives:
To do a systematic analysis of available literature regarding the association between COVID-19 vaccination and the first onset or flare of PMR and/or GCA.
Design:
Systematic review of case reports and case series.
Data sources and methods:
A systematic literature search was conducted using PubMed/MEDLINE, Cochrane, ScienceDirect, and Google Scholar. Data on patient demographics, clinical features, outcomes, and latency periods were extracted and analyzed. Quality assessment of included studies was performed using the Joanna Briggs Institute Critical Appraisal Tool.
Results:
A total of 32 articles, documenting 50 new-onset cases (30 PMR and 20 GCA), were identified for inclusion. The mean age for patients with PMR was 71.06 years, and 72.85 years for GCA. A slight female predominance was observed (60%) for both PMR and GCA. Pfizer-BioNTech (48%) and AstraZeneca (38%) vaccines were most frequently associated with disease onset. The mean latency period from vaccination to symptom onset was 11.03 days for PMR and 5.3 days for GCA, indicating a temporal relationship. Most of these studies originated from North America and Europe mimicking the global scale of vaccination. Most patients responded well to symptomatic treatment with corticosteroids.
Conclusions:
There exists a temporal association between COVID-19 mRNA or viral vector-based vaccines and the onset of PMR and GCA. While causality is not proven, this review underscores the need for clinicians to be aware of this potential association to ensure timely diagnosis and treatment, particularly as booster vaccinations continue to be administered. Larger epidemiological studies with long-term follow-up are essential to further explore this association.
Gonzalez-GayMAVazquez-RodriguezTRLopez-DiazMJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454-1461.
SmithJHSwansonJW.Giant cell arteritis. Headache J Head Face Pain. 2014;54:1273-1289.
4.
ButtgereitFDejacoCMattesonELDasguptaB.Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315:2442-2458.
5.
FalsettiPConticiniEAcciaiC, et al. Polymyalgia rheumatica following infective triggers or vaccinations: a different subset of disease?Reumatologia. 2020;58:76.
6.
PacoureauLBardeFSerorRNguyenY.Association between infection and the onset of giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis. RMD Open. 2023;9(4):e003493. Accessed September 18, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649904/
JarrotPAMirouseAOttavianiS, et al. Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: results from a nationwide survey. Hum Vaccines Immunother. 2024;20:2334084.
10.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg Lond Engl. 2021;88:105906.
11.
PonteCGraysonPCRobsonJC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81:1647-1653.
12.
DasguptaBCimminoMAMaradit-KremersH, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71:484-492.
13.
AhmadABakerDL.An unusual side effect of the COVID-19 vaccine: a possible trigger of polymyalgia rheumatica. Cureus. 2022;14:e26617.
14.
Al-AllafAWNeethuMAl-AllafY.A Case series and literature review of the association of COVID-19 vaccination with autoimmune diseases: causality or chance?Cureus. 2022;14:e28677.
15.
CadiouSPerdrigerAArdoisS, et al. SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: “Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?” by Manzo et al. Joint Bone Spine. 2022;89:105282.
16.
FurrTGargM.Rare Cases of Polymyalgia Rheumatica After Receiving COVID-19 Vaccinations. Cureus. 2023;15:e37782.
Poster presentations. Int J Rheum Dis. 2021;24:121-333.
19.
IzukaSKomaiTNatsumotoBShodaHFujioK.Self-limited polymyalgia rheumatica-like syndrome following mRNA-1273 SARS-CoV-2 vaccination. Intern Med Tokyo JPN. 2022;61:903-906.
20.
LourençoCPascoalAPaivaACamposIPagaimoJ.Polymyalgia rheumatica after ChAdOx1 nCov-19 vaccine: a case report. Cureus. 2022;14:e25346.
21.
ManzoCNataleMCastagnaA.Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: a case report and review of literature. Aging Med Milton NSW. 2021;4:234-238.
22.
MoharebMBharadwajANandagudiA.P061 Polymyalgia rheumatica following COVID-19 vaccination: presentation of four patients. Rheumatology. 2022;61:keac133060.
23.
OsadaASakuragiCToyaCMitsuoA.New-onset polymyalgia rheumatica following the administration of the Pfizer-BioNTech COVID-19 vaccine. Intern Med Tokyo JPN. 2022;61:749-753.
24.
OttavianiSJugePAForienMEbsteinEPalazzoEDieudéP.Polymyalgia rheumatica following COVID-19 vaccination: a case-series of ten patients. Joint Bone Spine. 2022;89:105334.
25.
SafaryAEsalatmaneshKEftekharsadatATJafari NakjavaniMRKhabbaziA.Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination. Int Immunopharmacol. 2022;110:109061.
26.
VanniECiaffiJMancarellaLUrsiniF.An Unusual Case of “Conjugal” Polymyalgia Rheumatica after SARS-CoV-2 Vaccination. Rheumato. 2021;1:17-21.
27.
WatadADe MarcoGMahajnaH, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines. 2021;9:435.
28.
YamadaSYamadaKNishidaH.A case of sequential development of polymyalgia rheumatica and Guillain-Barré syndrome following administration of the Pfizer-BioNTech COVID-19 vaccine. Intern Med Tokyo JPN. 2022;61:2995.
29.
YokoteAFujiokaSTakahashiNMishimaTTsuboiY.Polymyalgia rheumatica following COVID-19 vaccination. Intern Med Tokyo JPN. 2022;61:1775-1777.
30.
AnzolaAMTrivesLMartínez-BarrioJPinillaBÁlvaro-GraciaJMMolina-ColladaJ.New-onset giant cell arteritis following COVID-19 mRNA (BioNTech/Pfizer) vaccine: a double-edged sword?Clin Rheumatol. 2022;41:1623-1625. [Accessed October 3, 2024]. https://pubmed.ncbi.nlm.nih.gov/35112193/
31.
AriasMCacabelosPArias-RivasS.Polymyalgia rheumatica and giant cell arteritis with intracranial involvement postvaccination anti-COVID-19. Med Clin Engl Ed. 2022;159:e43-44.
32.
BouniaCKefalopoulouZVeltsistaDChroniELiossisSNC. Man-in-a-barrel syndrome: a rare presentation of giant cell arteritis. Clin Exp Rheumatol. 2022;40:838-840.
33.
CheSALeeKYYooYJ.Bilateral ischemic optic neuropathy from giant cell arteritis following COVID-19 vaccination. J Neuro Ophthalmol off J North Am Neuro Ophthalmol Soc. 2023;43:e107-108.
34.
DhunganaBDubeyS.Two cases of giant cell arteritis following ChAdOx1 nCoV—19 vaccination—complication or coincidence?J Clin Med Images Case Rep. 2022;2:1056. Accessed October 3, 2024. https://jcmimagescasereports.org/article/JCM-V1-1056.pdf
35.
GilioMDe StefanoG.Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine. Intern Emerg Med. 2022;17:1239-1241.
36.
GrebCSAouhabZSisbarroDPanahE.A case of giant cell arteritis presenting after COVID-19 vaccination: is it just a coincidence?Cureus. 2022;14:e21608.
37.
IshizukaDKKatayamaKOhiraY.Giant cell arteritis presenting with chronic cough and headache after BNT162b2 mRNA COVID-19 vaccination. QJM Mon J Assoc Physicians. 2022;115:621-622.
Lo SardoLParisiSDittoMC, et al. New onset of giant cell arteritis following ChAdOx1-S (Vaxevria®) vaccine administration. Vaccines. 2023;11:434.
40.
SauretAStievenartJSmetsP, et al. Case of Giant Cell Arteritis after SARS-CoV-2 vaccination: a particular phenotype?J Rheumatol. 2022;49:120.
41.
ShiYFMalikS.A Giant Silence—an atypical association of sensorineural hearing loss with Giant Cell Arteritis. Int J Rheum Dis. 2022;25:1203-1207.
42.
UrsiniFRuscittiPRaimondoV, et al. Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. Clin Rheumatol. 2022;41:2261-2267.
43.
WakabayashiHIwayanagiMSakaiD, et al. Development of giant cell arteritis after vaccination against SARS-CoV2: a case report and literature review. Medicine (Baltimore). 2023;102:e33948.
44.
XiaCEdwardsROmidvarB.A case of giant cell arteritis with a normal Erythrocyte Sedimentation Rate (ESR) post ChAdOx1 nCoV-19 vaccination. Cureus. 2022;14:e25388.
45.
AromatarisEFernandezRGodfreyCMHollyCKhalilHTungpunkomP.Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13:132-140.
46.
BandinelliFNassiniRGherardiE, et al. Small fiber neuropathy associated with post-COVID-19 and post-COVID-19 vaccination arthritis: a rare post-infective syndrome or a new-onset disease?J Pers Med. 2024;14:789. doi:10.3390/jpm14080789
47.
TomelleriAvan der GeestKSMKhurshidMA, et al. Disease stratification in GCA and PMR: state of the art and future perspectives. Nat Rev Rheumatol. 2023;19:446-459.
48.
SorianoAVerrecchiaEMarinaroA, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus. 2012;21:153-157.
49.
LiozonEParreauSFillouxM, et al. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review. Autoimmun Rev. 2021;20:102732.
50.
SiddiqiNGulatiGWareAE.Polymyalgia rheumatica and autoimmune inflammatory syndrome induced by adjuvants following administration of influenza vaccine. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2018;24:410-412.
51.
El LabbanMOluicSGuleidHHassanMDiabRRidaMA. Polymyalgia rheumatica following Respiratory Syncytial Virus (RSV) vaccination. Eur J Case Rep Intern Med. 2024;11:004636.
52.
TshimologoMSaundersBMullerSMallenCDHiderSL.Patients’ views on the causes of their polymyalgia rheumatica: a content analysis of data from the PMR Cohort Study. BMJ Open. 2017;7:e014301.
53.
HysaEGotelliESammorìS, et al. Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review. Autoimmun Rev. 2022;21:102995.
54.
SchäferVSBrossartPWarringtonKJKurtsCSendtnerGWAdenCA.The role of autoimmunity and autoinflammation in giant cell arteritis: a systematic literature review. Autoimmun Rev. 2023;22:103328.
55.
Gonzalez-GayMAGarcia-PorruaCMiranda-FilloyJAMartinJ.Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management. Drugs Aging. 2006;23:627-649.
56.
WongLAYapCGJahanNKPillaiN.COVID-19 vaccine: review of the mechanism of action of different types of vaccine Li-Ann Wong*, Christina Gertrude Yap, Nowrozy Kamar Jahan, Naganathan Pillai. Open Access Libr J. 2022;9:e8624.
57.
ChenYXuZWangP, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165:386-401.
58.
BandinelliFPaganoMVallecocciaMS.Post-COVID-19 and post-COVID-19 vaccine arthritis, polymyalgia rheumatica and Horton’s arteritis: a single-center assessment of clinical, serological, genetic, and ultrasonographic biomarkers. J Clin Med. 2023;12:7563. doi:10.3390/jcm12247563
59.
LallyLBloosteinAJannat-KhanDSpieraR.AB1308 polymyalgia rheumatica following SARSCoV-2 vaccination: a single center cohort study. Ann Rheum Dis. 2023;82.
60.
HysaECasabellaAGotelliE, et al. Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms. Autoimmun Rev. 2024;23:103589.
61.
MettlerCJonville-BeraAPGrandvuilleminATreluyerJMTerrierBChouchanaL.Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. Rheumatology. 2022;61:865-867.
62.
PolackFPThomasSJKitchinN, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-2615.
63.
MirandaSChaignotCCollinCDray-SpiraRWeillAZureikM.Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France. Vaccine. 2017;35:4761-4768.
64.
GrönlundOHerweijerESundströmKArnheim-DahlströmL.Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. J Intern Med. 2016;280:618-626.
65.
Ruhrman-ShaharNTorres-RuizJRotman-PikielnyPLevyY.Autoimmune reaction after anti-tetanus vaccination-description of four cases and review of the literature. Immunol Res. 2017;65:157-163.
66.
LegoutLHachullaEChérinP, et al. [Autoimmune diseases and vaccination against hepatitis B: should our patients be vaccinated?]. Rev Med Interne. 2001;22:402-405.
67.
SqueriR.HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature. J Prev Med Hyg. 2018;59:E194-E194.
68.
PetrášMLesnáIKDáňováJČelkoAM.Can vaccination trigger autoimmune disorders? A meta-analysis. Vaccines. 2021;9:821.
69.
MetyasSChenCAungTBallesterACheavS.Rheumatologic manifestations of post SARS-CoV-2 infection: a case series. Curr Rheumatol Rev. 2022;18:346-351.
70.
BandinelliFDi CarloMColantuonoVA, et al. Post-COVID-19 small fiber neuropathy as a new emerging quality of life-threatening disease: a systematic review. Microorganisms. 2025;13:328. doi:10.3390/microorganisms13020328
71.
SharmaAMohammadAJTuressonC.Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum. 2020;50:1040-1048.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
